- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT04939441
Regresión de la fibrosis hepática por tenofovir alafenamida (TAF)
Regression of Liver Fibrosis by Tenofovir Alafenamide (TAF) in Treatment-Naive CHB Related Fibrosis/Cirrhosis: a 240 Weeks Open-label Multicenter Study
Tenofovir alafenamide (TAF) is a new prodrug of tenofovir developed to treat patients with chronic hepatitis B virus (HBV) infection. Whereas, the long-term effect of TAF to liver fibrosis is still unknown. Here, we enrolled treatment naive CHB patients with biopsy-proven significant fibrosis (METAVIR fibrosis stage ≥ F2). To characterize longitudinal histological changes and assess liver fibrosis regression, the second and third liver biopsies are planned at weeks 96 and 240, respectively. During this study, all subjects will be assessed for laboratory tests, imaging examination at baseline, first 12-week and every 24-week during follow-up.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Tipo de estudio
Inscripción (Estimado)
Fase
- Fase 4
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Jidong Jia
- Número de teléfono: 86-010-63139246
- Correo electrónico: jia_jd@ccmu.edu.cn
Copia de seguridad de contactos de estudio
- Nombre: Jialing Zhou
- Número de teléfono: 86-010-63138665
- Correo electrónico: zhoujialing11@126.com
Ubicaciones de estudio
-
-
-
Beijing, Porcelana, 100069
- Reclutamiento
- Beijing YouAn Hospital, Capital Medical University
-
Contacto:
- Huiguo Ding, Doctoral degree
- Número de teléfono: 86-13911683832
- Correo electrónico: dinghuiguo@medmail.com.cn
-
Investigador principal:
- Huiguo Ding, Doctor
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, Porcelana, 100015
- Reclutamiento
- Beijing Ditan Hospital, Capital Medical University
-
Contacto:
- Wen Xie
- Correo electrónico: xiewen6218@163.com
-
-
Jiangsu
-
Suzhou, Jiangsu, Porcelana, 215131
- Reclutamiento
- The Fifth People's Hospital of Suzhou
-
Contacto:
- Chuanwu Zhu, Doctoral degree
- Número de teléfono: 86-13606202525
- Correo electrónico: zhuchw@126.com
-
-
Jiangxi
-
Nanchang, Jiangxi, Porcelana, 330006
- Reclutamiento
- The Ninth Hospital of Nanchang
-
Contacto:
- Yali Zong, Doctoral degree
- Número de teléfono: 86-13907004199
- Correo electrónico: zylnc@163.com
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, Porcelana, 200040
- Reclutamiento
- Huashan Hospital Fudan University
-
Contacto:
- Jiming Zhang
- Número de teléfono: 86-13816317838
- Correo electrónico: jmzhang@fudan.edu.cn
-
Shanghai, Shanghai Municipality, Porcelana, 200021
- Reclutamiento
- Shuguang Hospital
-
Contacto:
- Chenghai Liu
- Correo electrónico: chenghailiu@hotmail.com
-
Shanghai, Shanghai Municipality, Porcelana, 201199
- Reclutamiento
- Ruijin Hospital
-
Contacto:
- Qing Xie
- Número de teléfono: 86-13651804273
- Correo electrónico: xieqingrjh@163.com
-
-
Tianjin Municipality
-
Tianjin, Tianjin Municipality, Porcelana, 300170
- Reclutamiento
- Tianjin Third Central Hospital
-
Contacto:
- Tao Han
- Correo electrónico: hantaomd@126.com
-
Tianjin, Tianjin Municipality, Porcelana, 300192
- Reclutamiento
- Tianjin Second People's Hospital
-
Contacto:
- Ping Li
- Número de teléfono: 86-13920265719
- Correo electrónico: tjlplxg@163.com
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- 18-69 years old (inclusive);
- BMI (18-30 kg/m2);
- Chronic hepatitis B virus (HBV) infection, defined as positive serum hepatitis B s-antigen (HBsAg) for more than 6 months; or chronic hepatitis B proven by live biopsy;
- Not received nucleoside (acid) analogue and/or interferon therapy (treatment-naive);
- Liver biopsy performed within 6 months before treatment and had readable biopsy slides or agrees to have a biopsy performed prior to baseline;
- METAVIR fibrosis stage ≥ F2;
- For patients without cirrhosis (F2/3), HBV DNA levels >2000 IU/mL before treatment; For patients with cirrhosis (F4), HBV DNA >20 IU/mL before treatment;
- ALT≤10 ULN before treatment;
- Creatinine clearance ≥ 50 mL/min;
- Agreement not to undertake other HBV systemic antiviral or interferon (IFN) regimens during participation in this study;
- Willing and able to provide written informed consent.
Exclusion Criteria:
- Patients with Child-Turcotte-Pugh(CTP)score ≥ 7;
- Patients with decompensated cirrhosis: including ascites, hepatic encephalopathy, esophageal varices bleeding or other complications of decompensated cirrhosis or liver transplantation;
- Patients co-infection with hepatitis C virus (HCV), human immunodeficiency virus (HIV), or hepatitis delta virus (HDV), or alcoholic liver diseases, autoimmune liver disease, genetic liver disease, drug-induced liver injury, non-alcoholic fatty liver disease or other chronic liver diseases;
- Patients with evidence of hepatocellular carcinoma (HCC) by imaging with or without AFP;
- Patients with other uncured malignant tumors;
- Patients with organ or bone marrow transplantation;
- Patients currently receiving therapy with immunomodulators (eg, corticosteroids, etc.), investigational agents, nephrotoxic agents, or agents susceptible of modifying renal excretion;
- Patients who are allergic to any component of TAF;
- Patients who recently or newly started bisphosphate (within 1 month);
- Patients with active alcohol or drug abuse or history of alcohol or drug abuse (hinder compliance with treatment, or participation in the study or interpretation of results considered by the Investigator);
- Patients with significant renal, cardiovascular, pulmonary, or neurological disease
- Males and females of reproductive potential who are unwilling to use an effective method of contraception during the study;
- Pregnant women, women who are breast feeding or who believe they may wish to become pregnant during the course of the study;
- Not suitable for this study identified by researchers.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: N / A
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: TAF group
TAF [Vemlidy® 25mg QD] monotherapy |
Subjects will be treated for 240 weeks with TAF [Vemlidy® 25mg QD] monotherapy
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Proportion of patients with fibrosis regression
Periodo de tiempo: Week 96 and 240
|
Fibrosis stage decrease at least 1 point by Ishak score or "Predominantly Regressive" by "Beijing classification" |
Week 96 and 240
|
|
HBV DNA undetectable rate
Periodo de tiempo: Week 96
|
Serum HBV DNA <20 IU/mL |
Week 96
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Percentage of liver stiffness decrease >= 30%
Periodo de tiempo: Week 48, week 96, week 144, week 192 and week 240
|
Proportion of patients with liver stiffness decrease >= 30% from baseline to week 240 |
Week 48, week 96, week 144, week 192 and week 240
|
|
HBV DNA undetectable rate
Periodo de tiempo: Week 24, week 48, week 72, week 144, week 192 and week 240
|
HBV DNA undetectable rate at week 24, 48, 72, 144, 192 and 240 |
Week 24, week 48, week 72, week 144, week 192 and week 240
|
|
ALT normalization rate
Periodo de tiempo: Week 48, week 96, week 144, week 192 and week 240
|
Proportion of patients with ALT <= 1.0xULN |
Week 48, week 96, week 144, week 192 and week 240
|
|
HBeAg and HBsAg loss and seroconversion rate
Periodo de tiempo: Week 48, week 96, week 144 and week 240
|
Proportions of patients with HBsAg loss and seroconversion to anti-HBs, and proportions of patients with HBeAg loss and seroconversion to anti-HBe. |
Week 48, week 96, week 144 and week 240
|
|
Changes in renal function
Periodo de tiempo: Week 48, week 96, week 144, week 192 and week 240
|
Changes of eGFR (estimated Glomerular Filtration rate) from baseline to week 48, 96, 144, 192 and 240. |
Week 48, week 96, week 144, week 192 and week 240
|
|
Changes of bone mineral density
Periodo de tiempo: Week 48, week 96, week 144, week 192 and week 240
|
Percentage changes in spine BMD and hip BMD from baseline to week 48, 96, 144, 192 and 240 |
Week 48, week 96, week 144, week 192 and week 240
|
|
Incidence of liver-related endpoint events
Periodo de tiempo: Week 96 and week 240
|
liver-related endpoint events: decompensation, HCC, liver transplantation, liver-related death |
Week 96 and week 240
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Jidong Jia, Beijing Friendship Hospital, Capital Medical Hospital
Publicaciones y enlaces útiles
Publicaciones Generales
- Marcellin P, Gane E, Buti M, Afdhal N, Sievert W, Jacobson IM, Washington MK, Germanidis G, Flaherty JF, Aguilar Schall R, Bornstein JD, Kitrinos KM, Subramanian GM, McHutchison JG, Heathcote EJ. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet. 2013 Feb 9;381(9865):468-75. doi: 10.1016/S0140-6736(12)61425-1. Epub 2012 Dec 10.
- Buti M, Fung S, Gane E, Afdhal NH, Flisiak R, Gurel S, Flaherty JF, Martins EB, Yee LJ, Dinh P, Bornstein JD, Mani Subramanian G, Janssen HL, George J, Marcellin P. Long-term clinical outcomes in cirrhotic chronic hepatitis B patients treated with tenofovir disoproxil fumarate for up to 5 years. Hepatol Int. 2015 Apr;9(2):243-50. doi: 10.1007/s12072-015-9614-4. Epub 2015 Mar 13.
- Agarwal K, Brunetto M, Seto WK, Lim YS, Fung S, Marcellin P, Ahn SH, Izumi N, Chuang WL, Bae H, Sharma M, Janssen HLA, Pan CQ, Celen MK, Furusyo N, Shalimar D, Yoon KT, Trinh H, Flaherty JF, Gaggar A, Lau AH, Cathcart AL, Lin L, Bhardwaj N, Suri V, Mani Subramanian G, Gane EJ, Buti M, Chan HLY; GS-US-320-0110; GS-US-320-0108 Investigators. 96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection. J Hepatol. 2018 Apr;68(4):672-681. doi: 10.1016/j.jhep.2017.11.039. Epub 2018 Jan 17.
- Chan HL, Fung S, Seto WK, Chuang WL, Chen CY, Kim HJ, Hui AJ, Janssen HL, Chowdhury A, Tsang TY, Mehta R, Gane E, Flaherty JF, Massetto B, Gaggar A, Kitrinos KM, Lin L, Subramanian GM, McHutchison JG, Lim YS, Acharya SK, Agarwal K; GS-US-320-0110 Investigators. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol. 2016 Nov;1(3):185-195. doi: 10.1016/S2468-1253(16)30024-3. Epub 2016 Sep 22.
- Buti M, Gane E, Seto WK, Chan HL, Chuang WL, Stepanova T, Hui AJ, Lim YS, Mehta R, Janssen HL, Acharya SK, Flaherty JF, Massetto B, Cathcart AL, Kim K, Gaggar A, Subramanian GM, McHutchison JG, Pan CQ, Brunetto M, Izumi N, Marcellin P; GS-US-320-0108 Investigators. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol. 2016 Nov;1(3):196-206. doi: 10.1016/S2468-1253(16)30107-8. Epub 2016 Sep 22.
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Infecciones transmitidas por la sangre
- Procesos Patológicos
- Enfermedad crónica
- Atributos de la enfermedad
- Infecciones
- Enfermedades virales
- Enfermedades del Sistema Digestivo
- Enfermedades del HIGADO
- Hepatitis, Viral, Humana
- Enfermedades contagiosas
- Infecciones por virus de ADN
- Infecciones por Hepadnaviridae
- Fibrosis
- Hepatitis Crónica
- Hepatitis
- Condiciones Patológicas, Signos y Síntomas
- Hepatitis B
- Hepatitis B Crónica
- Cirrosis hepática
- tenofovir alafenamida
Otros números de identificación del estudio
- IN-CN-320-5613
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
We will consider sharing it after the primary outcome is published.
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .